MLchartDataset catalogue

anti-inflammatory antibody ALXN1007

Term · Oncology and biomedicine · MLC-T-ONC-010822

A proprietary antibody that targets the complement inflammatory pathway with potential immunomodulating and anti-inflammatory activities. Upon intravenous administration, anti-inflammatory antibody ALXN1007 modulates the complement inflammatory pathway through binding to an as of yet undisclosed target. This may help in the treatment of certain inflammatory-mediated disorders, such as antiphospholipid syndrome (APS). This agent may also influence the progression of graft-versus-host disease (GvHD).

Table 1. Record
IdentifierMLC-T-ONC-010822
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010822",
  "term": "anti-inflammatory antibody ALXN1007",
  "field": "Oncology and biomedicine",
  "definition": "A proprietary antibody that targets the complement inflammatory pathway with potential immunomodulating and anti-inflammatory activities. Upon intravenous administration, anti-inflammatory antibody ALXN1007 modulates the complement inflammatory pathway through binding to an as of yet undisclosed target. This may help in the treatment of certain inflammatory-mediated disorders, such as antiphospholipid syndrome (APS). This agent may also influence the progression of graft-versus-host disease (GvHD).",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-inflammatory-antibody-alxn1007/"
}

Record 1,939 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.